Warning letter
Lymol Medical Corporation: warning letter of Apr 7, 2020
FDA warning letter 606833 · Office of Medical Device and Radiological Health Operations (Division 1 East)
Key facts
| Reference number | 606833 |
|---|---|
| Company | Lymol Medical Corporation |
| Subject | CGMP/QSR/Medical Devices/Adulterated |
| Issue date | Apr 7, 2020 |
| Posted date | May 19, 2020 |
| Issuing office | Office of Medical Device and Radiological Health Operations (Division 1 East) |
| Product type | Devices |
| CFR sections cited | 820 |
| Inspection city | Woburn |
| Inspection ZIP | 01801 |
| Inspection start date | Feb 3, 2020 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: